anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Traction

Slide type collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 10,471
Current window 6,241-6,270
Pages 350
Rows per page 30
Slide type: Tractionclear collectionreset all
18 30 60

Slide type

6,241-6,270 of 10,471

filter-aware
15
Includes photos of LION6 truck and LIONC school buses.Lion Electric | Investor Presentation Deck | 30 slides · Lion Electric
Pitch deck Investor relations 1 hit
11
This slide serves as a validation/traction point by highlighting a partnership with a major pharmaceutical company.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
13
The slide outlines a multi-part clinical trial process (Part A, Part B, and Expansion) for NSCLC 2L patients.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
17
Data presented in a table format with footnotes explaining the methodology for DCR calculation.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
21
The plot highlights long-term benefit post-therapy and low mortality rates in the cohort.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
24
Includes two line charts showing tumor volume reduction and rechallenge success.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
28
The slide presents two line charts showing tumor volume reduction over time for different treatment regimens in SCLC and HCC models.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
29
The chart shows tumor volume over time, with the THIO group reaching 100% complete response (CR).MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
30
The slide shows two line charts representing tumor volume over time in HCC models, highlighting the efficacy of THIO and THIO+Libtayo combinations.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
39
The slide serves as a milestone marker for the company's public listing.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
08
The chart uses a dual-axis approach to show both per-share metrics and NAV growth over time.Main Street Capital | Investor Presentation Deck | 49 slides · Main Street Capital Corporation
Pitch deck Investor relations 1 hit
17
The chart highlights specific periods like the 'Recessionary Period' and 'COVID Pandemic Period' to demonstrate dividend stability.Main Street Capital | Investor Presentation Deck | 49 slides · Main Street Capital Corporation
Pitch deck Investor relations 1 hit
18
The chart uses a stacked bar approach to distinguish between monthly and supplemental dividends, with annotations for recessionary and pandemic periods.Main Street Capital | Investor Presentation Deck | 49 slides · Main Street Capital Corporation
Pitch deck Investor relations 1 hit
24
LMM stands for Lower Middle Market. The slide uses a mix of bulleted lists to present financial performance and portfolio quality.Main Street Capital | Investor Presentation Deck | 49 slides · Main Street Capital Corporation
Pitch deck Investor relations 1 hit
34
Includes year-over-year percentage changes for each period.Main Street Capital | Investor Presentation Deck | 49 slides · Main Street Capital Corporation
Pitch deck Investor relations Beat · Financials1 hit
35
The chart uses a combination of bar and line graphs to demonstrate long-term financial performance.Main Street Capital | Investor Presentation Deck | 49 slides · Main Street Capital Corporation
Pitch deck Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
46
The chart highlights significant market events including the 2008 recessionary period and the COVID-19 pandemic.Main Street Capital | Investor Presentation Deck | 49 slides · Main Street Capital Corporation
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
09
The slide uses a 3-column layout to categorize achievements by strategic pillar.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
15
The slide features a thumbnail of a scientific poster presentation.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
18
Includes a highlight box around the primary performance metrics for CRC and AA.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
11
The slide uses a process flow diagram to map clinical outcomes to specific data points.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
12
This is a credibility-building slide showcasing academic validation of the company's technology.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
14
Focuses on patients who failed or could not tolerate standard azole or IV Amphotericin B therapies.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
21
The slide uses a matrix-like structure to map disease areas (Infection, Inflammation, Oncology) to specific animal models and clinical indications.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
22
Data presented as a multi-panel chart comparing Uninfected, Infected Untreated, SQ Remdesivir, and Oral LNC-Remdesivir groups.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
23
The chart demonstrates high uptake efficiency of LNC-formulated oligos over time across different cell types.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
24
The chart shows dose-dependent inhibition; LNC formulations consistently outperform Taxol.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
26
The chart shows a clear dose-response relationship with increasing efficacy of the LNC formulation at 2.5, 5, and 10 nM doses.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
04
Includes a footer with brand logos and a disclaimer about non-GAAP measures.Membership Collective Group | Investor Presentation Deck | 31 slides · Soho House & Co Inc.
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
07
Membership Collective Group | Investor Presentation Deck | 31 slidesMembership Collective Group | Investor Presentation Deck | 31 slides · Soho House & Co Inc.
Pitch deck Investor relations Loop · Cost Of Inaction1 hit